关于癌症适应性治疗周期的设计和稳定性:决定性和随机模型
Yuri G Vilela1, Artur C Fassoni2, Armando G M Neves1
1Department of Mathematics, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos, 6627, 31270-901, Belo Horizonte, MG, Brazil.
Mathematical biosciences
|July 17, 2025
概括
适应疗法使用循环药物治疗来延迟癌症的耐药性. 稳定的决定性循环确保了强大的瘤控制,即使随机细胞变异,提高临床性.
科学领域:
- 数学瘤学数学瘤学
- 计算生物学 计算生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 适应疗法利用癌细胞竞争来延迟耐药性.
- 循环药物管理在确定性模型中显示出恢复瘤组成的前景.
研究的目的:
- 研究设计稳定的循环适应疗法的条件和方法.
- 在确定性和随机性癌症模型中分析这些周期的稳定性.
主要方法:
- 开发了在Lotka-Volterra中构建循环的生物动机条件,并调整了复制器动力学.
- 为使用两种药物和无药周期的周期设计了算法.
- 分析了周期稳定性和研究了随机对应物.
主要成果:
- 稳定的确定性周期在随机模型中导致稳定的周期性行为,尽管随机波动.
- 随机设置中的周期分解与底层决定性周期的不稳定性有关.
- 稳定的周期表现出对随机模型的崩的长期稳定性.
结论:
- 确定性周期稳定性对于适应性癌症治疗中的随机稳定性至关重要.
- 为设计临床弹性适应性疗法提供了一个理论框架.
- 强调稳定性分析对于循环处理的实际应用的重要性.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K


